Tab%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520genixim

# Tabgenixim ## Overview Tabgenixim is a brand name for a fixed-dose combination of amoxicillin and clavulanate potassium, an extended-spectrum penicillinase-resistant penicillin and a beta-lactamase inhibitor, respectively. ## Primary Indications * Bacterial infections due to susceptible organisms, including: * Lower respiratory tract infections (e.g., chronic bronchitis exacerbations, community-acquired pneumonia) * Otitis media, sinusitis, and other upper respiratory tract infections * Skin and skin-structure infections * Urinary tract infections (complicated and uncomplicated) * Bone and joint infections ## Adult Dosing * **Standard Regimens:** Dosing is based on the amoxicillin component. Common doses include: * **500 mg / 125 mg:** One tablet orally every 12 hours. * **875 mg / 125 mg:** One tablet orally every 12 hours. * **Maximum Dose:** Do not exceed 875 mg of amoxicillin every 12 hours. * Dosing frequency and duration depend on the severity of infection and is often guided by local protocols. ## Pediatric Dosing * Dosing is based on amoxicillin component and patient's weight. **Specific pediatric formulations (suspension) are generally preferred for accurate weight-based dosing.** * **General Guideline (for oral suspension, consult product labeling for specific strengths):** * **Mild-to-moderate infections:** 25 mg/kg/day in divided doses every 12 hours. * **Severe infections:** 45 mg/kg/day in divided doses every 12 hours. * **Maximum pediatric dose:** Should not exceed adult maximums. * **For children weighing 40 kg or more:** Prescribe as per adult dosing. ## Dose Adjustments * **Renal Impairment:** * **CrCl > 30 mL/min:** No dose adjustment generally needed. * **CrCl 10-30 mL/min:** * 500 mg/125 mg tablet: Administer one tablet every 12 hours OR one tablet every 24 hours (depending on severity). * 875 mg/125 mg tablet: Administer one tablet every 24 hours. * **CrCl < 10 mL/min:** * 500 mg/125 mg tablet: Administer one tablet every 48 hours. * 875 mg/125 mg tablet: Not recommended. * **Hepatic Impairment:** Use with caution. Monitor liver function. ## Contraindications * History of serious allergic reaction (e.g., anaphylaxis, Stevens-Johnson syndrome) to penicillins, cephalosporins, or other beta-lactam antibiotics. * History of cholestatic jaundice/hepatic dysfunction associated with amoxicillin-clavulanate use. ## Adverse Effects * **Common:** Diarrhea, nausea, vomiting, rash, headache. * **Serious:** * **Hypersensitivity reactions:** Anaphylaxis, angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis. * **Hepatotoxicity:** Jaundice, elevated liver enzymes, hepatic failure (especially with prolonged use or in patients with pre-existing liver disease). * **Clostridioides difficile-associated diarrhea (CDAD).** * Seizures (rare, particularly with high doses or in patients with renal impairment). ## Key Drug Interactions * **Probenecid:** May increase and prolong blood levels of amoxicillin. * **Warfarin:** May alter prothrombin time; monitor INR closely. * **Oral Contraceptives:** May reduce efficacy; consider alternative contraception. * **Allopurinol:** Increased incidence of rash. * **Bacteriostatic agents (e.g., tetracyclines, macrolides):** May potentially antagonize the effect of penicillin. ## Monitoring * Evaluate for signs and symptoms of hypersensitivity reactions. * Monitor for diarrhea; assess for CDAD if it occurs. * Monitor liver function tests periodically, especially in patients with hepatic impairment or those on prolonged therapy. * Monitor INR if patient is also taking warfarin. ## Clinical Pearls * Administer with or without food. However, taking with food may reduce gastrointestinal upset. * Extended-release formulations are distinct from immediate-release tablets and have different dosing frequencies. Ensure the correct formulation is prescribed and dispensed. * Clavulanate potassium is added to protect amoxicillin from degradation by beta-lactamase enzymes. * Use should be based on susceptibility testing when available, but empiric therapy may be initiated based on clinical presentation. * The 875 mg/125 mg formulation is not recommended for patients with significant renal impairment (CrCl < 30 mL/min). *** **Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information or official drug compendium for complete details and to verify information before making clinical decisions.